Work

A phase II study evaluating bevacizumab in combination with fixed-dose rate gemcitabine and low-dose cisplatin for metastatic pancreatic cancer: is an anti-VEGF strategy still applicable?

Year: 2008

Type: article

Study design: Clinical Trial

Source: Investigational New Drugs

DOI: 10.1007/s10637-008-9127-2

Authors: Andrew H. Ko, Elizabeth Dito, Brian Schillinger, Alan P. Venook, Zhidong Xu, Emily K. Bergsland, Derrick Wong, Janet Scott, Jimmy Hwang, Margaret A. Tempero

Institutions: University of California, San Francisco, University of California San Francisco Medical Center, UCSF Helen Diller Family Comprehensive Cancer Center

Language: English

Topic: Pancreatic and Hepatic Oncology Research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funder: Genentech

OpenAlex ID: W2084555154

FWCI: 4.312

Cites: 36

Cited by: 71

Related to: 10